Kurt Graves, new i2o Therapeutics CEO
i2o Therapeutics closes $46M Series A, names Kurt Graves as CEO and acquires Intarcia’s twice-rejected diabetes asset
In a slew of company updates, i2o Therapeutics has closed a Series A raise worth $46 million from biotech investors and named Kurt Graves as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
